pantoprazole has been researched along with Gastritis in 46 studies
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
Gastritis: Inflammation of the GASTRIC MUCOSA, a lesion observed in a number of unrelated disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clarithromycin resistance was detected in 33/190 patients (17." | 5.51 | Clarithromycin resistance and female gender affect Helicobacter pylori eradication failure in chronic gastritis. ( Chang, YW; Cho, JH; Jang, JY; Kim, JW; Ko, WJ; Moon, JR; Oh, CH; Oh, SJ; Park, YM, 2019) |
| " pylori associated gastritis were randomly divided into pantoprazole triple regimen group (pantoprazole 40 mg, amoxicillin 1 g, and metronidazole 400 mg, bid,for 1-week or 2-weeks) and omeprazole triple regimen (omeprazole 20 mg, amoxicillin 1 g, and metronidazole 400 mg, bid, for 1-week or 2-weeks)." | 5.10 | [Comparison of pantoprazole and omeprazole-based triple therapy regimens in the treatment of Helicobacter pylori infection]. ( Cui, M; Hu, F; Jiang, H; Zheng, X, 2002) |
| "pylori positive (histology and/or culture) ulcer disease (n = 17; acute ulcer: n = 11) or functional dyspepsia (n = 13) were treated over one week with pantoprazole 40 mg bd, clarithromycin 250 mg bd and metronidazole 400 mg bd." | 5.08 | [Short-term triple therapy with pantoprazole, clarithromycin and metronidazole in eradication of Helicobacter pylori]. ( Becker, T; Börsch, G; Labenz, J; Peitz, U; Stolte, M; Tillenburg, B, 1995) |
| "Pantoprazole is a proton pump inhibitor that is commonly used in the treatment of peptic ulcer disease (PUD) and metabolized by cytochrome P450 (CYP) enzymes CYP2C19 and CYP3A4." | 3.85 | Effects of Genetic Polymorphisms of Cytochrome P450 Enzymes and MDR1 Transporter on Pantoprazole Metabolism and Helicobacter pylori Eradication. ( Altinbas, A; Babaoglu, MO; Bozkurt, A; Goktas, MT; Kalkisim, S; Karaca, RO; Kilincalp, S; Yasar, U; Yuksel, I, 2017) |
| "The development of eosinophilic gastritis immediately after Helicobacter pylori eradication has not previously been described: A 62-year-old woman developed eosinophilic gastritis immediately after a triple therapy for Helicobacter pylori eradication, consisting of pantoprazole, amoxicillin and clarithromycin." | 3.74 | [Eosinophilic gastritis after helicobacter pylori eradication]. ( Aigner, T; Fritzsch, J; Krügel, V; Pluta, L; Schütz, A, 2008) |
| "This is our final report on the clinical effectiveness and safety of long-term pantoprazole in patients with severe peptic ulcer or reflux disease during continuous treatment for up to 5 years." | 3.73 | Pantoprazole in severe acid-peptic disease: the effectiveness and safety of 5 years' continuous treatment. ( Bardhan, KD; Bishop, AE; Luehmann, R; McCaldin, B; Morris, P; Polak, JM; Romanska, HM; Rowland, A; Schaefer-Preuss, S; Thompson, M, 2005) |
| "SUMMARY Eradikacion therapy at patients with chronic pancreatitis and combined with Helicobacter associated erosive gastropathy in a month after treatment appeared successful at 75% patients which accepted therapy of the first line--pantoprazol, amoksicillin, klaritromicin." | 2.79 | [Estimation of efficiency of anti-helicobacter therapy in patients with a chronic pancreatitis combined with an erosive gastropathy]. ( Kotsiubniak, LA; Koval', VIu; Moskal', OM, 2014) |
| "Erdosteine is an efficient adjuvant therapy that could be used in conjunction with first-line triple therapy in the treatment of H." | 2.75 | Effect of the mucolytic erdosteine on the success rate of PPI-based first-line triple therapy for Helicobacter pylori eradication: a prospective, double-blind, randomized, placebo-controlled study. ( Abut, E; Bölükbaş, C; Bölükbaş, FF; Dalay, AR; Güveli, H; Kurdaş, OO; Yaşar, B, 2010) |
| " We performed serial endoscopy, checked for adverse events, and laboratory values." | 2.70 | Pantoprazole therapy in the long-term management of severe acid peptic disease: clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studies. ( Bardhan, KD; Bishop, AE; Cherian, P; Fischer, R; Lühmann, R; McCaldin, B; Morris, P; Ng, W; Perry, MJ; Polak, JM; Romanska, H; Rowland, A; Schneider, A; Thompson, M, 2001) |
| "Metronidazole resistance was found in 44% of pre-treatment cultures of H." | 2.69 | Triple therapy for Helicobacter pylori eradication: a comparison of pantoprazole once versus twice daily. ( Axon, AT; Bardhan, KD; Braun, W; Cooper, BT; Dillon, J; Gatz, G; Tildesley, G; Wyatt, JI, 2000) |
| "Clarithromycin resistance was detected in 33/190 patients (17." | 1.51 | Clarithromycin resistance and female gender affect Helicobacter pylori eradication failure in chronic gastritis. ( Chang, YW; Cho, JH; Jang, JY; Kim, JW; Ko, WJ; Moon, JR; Oh, CH; Oh, SJ; Park, YM, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (15.22) | 18.2507 |
| 2000's | 19 (41.30) | 29.6817 |
| 2010's | 19 (41.30) | 24.3611 |
| 2020's | 1 (2.17) | 2.80 |
| Authors | Studies |
|---|---|
| Asharaf, A | 1 |
| Desai, P | 1 |
| Sanati, M | 1 |
| Şenocak Taşçı, E | 1 |
| Akbaş, T | 1 |
| Chang, YW | 1 |
| Ko, WJ | 1 |
| Oh, CH | 1 |
| Park, YM | 1 |
| Oh, SJ | 1 |
| Moon, JR | 1 |
| Cho, JH | 1 |
| Kim, JW | 2 |
| Jang, JY | 1 |
| Krogulska, A | 1 |
| Grzelak-Czachorowska, K | 1 |
| Daniluk-Matraś, I | 1 |
| Kuczyńska, R | 1 |
| Szaflarska-Poplawska, A | 1 |
| Joosten, M | 1 |
| Flahou, B | 1 |
| Meyns, T | 1 |
| Smet, A | 1 |
| Arts, J | 1 |
| De Cooman, L | 1 |
| Pasmans, F | 1 |
| Ducatelle, R | 1 |
| Haesebrouck, F | 1 |
| Cecchini, MP | 1 |
| Pellegrini, C | 1 |
| Bassetto, MA | 1 |
| Osculati, F | 1 |
| Sbarbati, A | 1 |
| Marcolini, L | 1 |
| Pegoraro, M | 1 |
| Fontana, R | 1 |
| De Franceschi, L | 1 |
| Dhakal, M | 1 |
| Dhakal, OP | 1 |
| Bhandari, D | 1 |
| Gupta, A | 1 |
| Inci, F | 1 |
| Atmaca, M | 1 |
| Ozturk, M | 1 |
| Yildiz, S | 1 |
| Koceroglu, R | 1 |
| Sekeroglu, R | 1 |
| Ipekci, SH | 1 |
| Kebapcilar, L | 1 |
| Berry, AC | 1 |
| Nakshabendi, R | 1 |
| Baltz, AC | 1 |
| Metanat, HA | 1 |
| Valizadeh, SM | 1 |
| Fakheri, H | 1 |
| Maleki, I | 1 |
| Taghvaei, T | 1 |
| Hosseini, V | 1 |
| Bari, Z | 1 |
| Koval', VIu | 1 |
| Kotsiubniak, LA | 1 |
| Moskal', OM | 1 |
| Wagener, M | 1 |
| Park, SM | 1 |
| Kim, JS | 1 |
| Kim, BW | 1 |
| Ji, JS | 1 |
| Choi, H | 1 |
| Karaca, RO | 1 |
| Kalkisim, S | 1 |
| Altinbas, A | 1 |
| Kilincalp, S | 1 |
| Yuksel, I | 1 |
| Goktas, MT | 1 |
| Yasar, U | 1 |
| Bozkurt, A | 1 |
| Babaoglu, MO | 1 |
| Oh, JH | 1 |
| Dong, MS | 1 |
| Choi, MG | 1 |
| Yoo, HW | 1 |
| Lee, SB | 1 |
| Park, YI | 1 |
| Chung, IS | 1 |
| Dietrich, CG | 1 |
| Laupichler, S | 1 |
| Stanzel, S | 1 |
| Winograd, R | 1 |
| Al-Taie, O | 1 |
| Gartung, C | 1 |
| Geier, A | 1 |
| Fritzsch, J | 1 |
| Krügel, V | 1 |
| Aigner, T | 1 |
| Pluta, L | 1 |
| Schütz, A | 1 |
| Abut, E | 1 |
| Yaşar, B | 1 |
| Güveli, H | 1 |
| Bölükbaş, C | 1 |
| Bölükbaş, FF | 1 |
| Dalay, AR | 1 |
| Kurdaş, OO | 1 |
| Lassnig, RM | 1 |
| Harbaum, L | 1 |
| Siebert, F | 1 |
| Langner, C | 1 |
| Kim, JY | 1 |
| Kim, N | 1 |
| Park, HK | 1 |
| Jo, HJ | 1 |
| Shin, CM | 1 |
| Lee, SH | 1 |
| Park, YS | 1 |
| Hwang, JH | 1 |
| Jeong, SH | 1 |
| Lee, DH | 1 |
| Nam, RH | 1 |
| Kim, JM | 1 |
| Lee, JH | 1 |
| Jung, HC | 1 |
| Song, IS | 1 |
| Shcherbakov, PL | 1 |
| Ianova, OB | 1 |
| Belousova, NL | 1 |
| Masharova, AA | 1 |
| Shcherbakova, MIu | 1 |
| Goncharenko, LS | 1 |
| Firsova, LD | 1 |
| Kim, VA | 1 |
| Govorun, VM | 1 |
| Kashnikov, VS | 1 |
| Lings, K | 1 |
| Deleuran, M | 1 |
| Cui, M | 1 |
| Hu, F | 1 |
| Jiang, H | 1 |
| Zheng, X | 1 |
| Bardhan, KD | 3 |
| Bishop, AE | 2 |
| Polak, JM | 2 |
| Romanska, HM | 1 |
| Rowland, A | 2 |
| Thompson, M | 2 |
| Morris, P | 2 |
| Schaefer-Preuss, S | 1 |
| Luehmann, R | 1 |
| McCaldin, B | 2 |
| Marusic, M | 1 |
| Babic, Z | 1 |
| Nesanovic, M | 1 |
| Lucijanic-Mlinac, M | 1 |
| Stajcar, V | 1 |
| Pilotto, A | 1 |
| Perri, F | 2 |
| Leandro, G | 1 |
| Franceschi, M | 1 |
| Dietrich, JW | 1 |
| Boehm, BO | 1 |
| Ziemniak, W | 1 |
| Pakhomova, IG | 1 |
| Somberg, L | 1 |
| Morris, J | 1 |
| Fantus, R | 1 |
| Graepel, J | 1 |
| Field, BG | 1 |
| Lynn, R | 1 |
| Karlstadt, R | 1 |
| Labenz, J | 1 |
| Peitz, U | 1 |
| Tillenburg, B | 1 |
| Becker, T | 1 |
| Börsch, G | 1 |
| Stolte, M | 2 |
| Adamek, RJ | 1 |
| Szymanski, C | 1 |
| Pfaffenbach, B | 1 |
| Opferkuch, W | 1 |
| Ricken, D | 1 |
| Wegener, M | 1 |
| Ellenrieder, V | 2 |
| Fensterer, H | 1 |
| Waurick, M | 1 |
| Adler, G | 2 |
| Glasbrenner, B | 2 |
| Meier, E | 1 |
| Meining, A | 1 |
| Dattilo, M | 1 |
| Figura, N | 1 |
| Abdul Aal, GM | 1 |
| Dajani, AI | 1 |
| Nounou, M | 1 |
| Awad, S | 1 |
| Abdul Rasheed, Z | 1 |
| Gautam, S | 1 |
| Ukabam, S | 1 |
| Nayal, S | 1 |
| Boeck, W | 1 |
| Richter, C | 1 |
| Marre, R | 1 |
| Dillon, J | 1 |
| Axon, AT | 1 |
| Cooper, BT | 1 |
| Tildesley, G | 1 |
| Wyatt, JI | 1 |
| Gatz, G | 1 |
| Braun, W | 1 |
| Dammann, HG | 1 |
| Fölsch, UR | 1 |
| Hahn, EG | 1 |
| von Kleist, DH | 1 |
| Klör, HU | 1 |
| Kirchner, T | 1 |
| Strobel, S | 1 |
| Kist, M | 1 |
| Vukobrat-Bijedić, Z | 1 |
| Lacević, N | 1 |
| Bratović, I | 1 |
| Gribajcević, M | 1 |
| Gogov, B | 1 |
| Radović, S | 1 |
| Catalano, F | 1 |
| Catanzaro, R | 1 |
| Branciforte, G | 1 |
| Bentivegna, C | 1 |
| Cipolla, R | 1 |
| Brogna, A | 1 |
| Nuciforo, G | 1 |
| Giannini, E | 1 |
| Romagnoli, P | 1 |
| Fasoli, A | 1 |
| Chiarbonello, B | 1 |
| Malfatti, F | 1 |
| Botta, F | 1 |
| Risso, D | 1 |
| Lantieri, PB | 1 |
| Savarino, V | 1 |
| Testa, R | 1 |
| Festa, V | 1 |
| Clemente, R | 1 |
| Villani, MR | 1 |
| Quitadamo, M | 1 |
| Caruso, N | 1 |
| Bergoli, ML | 1 |
| Andriulli, A | 1 |
| Cherian, P | 1 |
| Romanska, H | 1 |
| Perry, MJ | 1 |
| Schneider, A | 1 |
| Fischer, R | 1 |
| Ng, W | 1 |
| Lühmann, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effectiveness of Rifabutin Triple Therapy for First-line and Rescue Treatment of Helicobacter Pylori Infection[NCT04652284] | Phase 3 | 300 participants (Anticipated) | Interventional | 2021-05-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for pantoprazole and Gastritis
| Article | Year |
|---|---|
Gastric xanthelasma: an unusual endoscopic finding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Biopsy, Needle; Chronic Disease; Follow-Up Studies; | 2013 |
[Eradication of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2005 |
Helicobacter pylori infection, chronic gastritis, and proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; C | 1998 |
25 trials available for pantoprazole and Gastritis
| Article | Year |
|---|---|
Comparison Between 10- and 14-Day Hybrid Regimens for Helicobacter pylori Eradication: A Randomized Clinical Trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; | 2015 |
[Estimation of efficiency of anti-helicobacter therapy in patients with a chronic pancreatitis combined with an erosive gastropathy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Th | 2014 |
Randomized clinical trial comparing 10- or 14-day sequential therapy and 10- or 14-day concomitant therapy for the first line empirical treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Clarithromycin; Drug Administration Sche | 2017 |
Effects of CYP2C19 and MDR1 genotype on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxycillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon | 2009 |
Origin of and therapeutic approach to cardiac syndrome X: results of the proton pump inhibitor therapy for angina-like lingering pain trial (PITFALL trial).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Chest Pain; Coronary Angiography; Double-Blind Method | 2008 |
Effect of the mucolytic erdosteine on the success rate of PPI-based first-line triple therapy for Helicobacter pylori eradication: a prospective, double-blind, randomized, placebo-controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Amoxicillin; Biopsy; Clarithro | 2010 |
[Enterofuril eradication therapy in chronic inflammatory diseases of the upper digestive tract].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Infective Agents; Chronic Disease; Clarithromyc | 2011 |
[Comparison of pantoprazole and omeprazole-based triple therapy regimens in the treatment of Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti | 2002 |
Influence of various proton pump inhibitors on intestinal metaplasia in noneradicated Helicobacter pylori patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; | 2005 |
Effect of Helicobacter pylori eradication on the outcome of reflux esophagitis and chronic gastritis in the elderly. A randomized, multicenter, eight-month study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents | 2006 |
Efficacy of Helicobacter pylori eradication taking into account its resistance to antibiotics.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2006 |
[Use of pantoprazol for treatment of gastroesophageal reflux disease and NSAID-induced gastropathy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Ster | 2007 |
Intermittent intravenous pantoprazole and continuous cimetidine infusion: effect on gastric pH control in critically ill patients at risk of developing stress-related mucosal disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Cimetidine; Drug Administration S | 2008 |
[Short-term triple therapy with pantoprazole, clarithromycin and metronidazole in eradication of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 1995 |
[Short-term triple therapy with pantoprazole, clarithromycin and metronidazole for the healing of Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Benzimidazoles; Biopsy; Clarithrom | 1995 |
Influence of clarithromycin dosage on pantoprazole combined triple therapy for eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 1998 |
Resolution of gastritis induced by Helicobacter pylori 4-5 weeks after successful eradication of infection using a triple therapy regimen of pantoprazole, amoxycillin and clarithromycin for one week.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Biopsy; Cla | 1999 |
Prevalence of resistance to clarithromycin and its clinical impact on the efficacy of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 1999 |
Triple therapy for Helicobacter pylori eradication: a comparison of pantoprazole once versus twice daily.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidaz | 2000 |
Eradication of H. pylori with pantoprazole, clarithromycin, and metronidazole in duodenal ulcer patients: a head-to-head comparison between two regimens of different duration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adult; Aged; Anti-Bacterial Agents; Anti-Ul | 2000 |
[Effect of pantoprazole, amoxicillin and metronidazole treatment on the level of H. pylori eradication and the histological image of antral gastritis in patients with duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2000 |
Five-day triple therapy in Helicobacter pylori-positive duodenal ulcer: an eighteen-month follow-up.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2000 |
Influence of Helicobacter pylori eradication therapy on 13C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aminopyrine; Anti-Ulcer Agents; Benzimidazoles | 2000 |
Randomized study of two "rescue" therapies for Helicobacter pylori-infected patients after failure of standard triple therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Benzimidaz | 2001 |
Pantoprazole therapy in the long-term management of severe acid peptic disease: clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; | 2001 |
18 other studies available for pantoprazole and Gastritis
| Article | Year |
|---|---|
Emphysematous Gastritis.
Topics: Abdominal Pain; Anti-Bacterial Agents; Anti-Ulcer Agents; Emphysema; Foreign Bodies; Gastritis; Huma | 2019 |
The Relationship between the Sydney Classification and the First-Line Treatment Efficacy in Helicobacter-Associated Gastritis.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chronic Disease; Clarithromycin; Clinic | 2020 |
Clarithromycin resistance and female gender affect Helicobacter pylori eradication failure in chronic gastritis.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Chronic Disease; Clarithromycin; Cytochrome P-450 CYP2C19; | 2019 |
Recurrent Nausea and Vomiting in a Teenager - A Rare Disease with Common Symptoms.
Topics: Adolescent; Anti-Ulcer Agents; Down Syndrome; Female; Gastric Outlet Obstruction; Gastritis; Gastros | 2019 |
Case report: Helicobacter suis infection in a pig veterinarian.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Animals; Anti-Bacterial Agents; Clarith | 2013 |
Might Helicobacter pylori infection be associated with distortion on taste perception?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Clarithromycin; Dysgeusia; Female; G | 2013 |
Pantoprazole may improve beta cell function and diabetes mellitus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Cohort Studies; | 2014 |
Not All Helicobacter Are pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anti-Bacterial Agents; Biopsy; Clarithromycin; | 2015 |
Haemotoxic snakebite in rural KwaZulu-Natal, South Africa: A case presenting with haematemesis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Antivenins; Crystalloid Solutions | 2016 |
Effects of Genetic Polymorphisms of Cytochrome P450 Enzymes and MDR1 Transporter on Pantoprazole Metabolism and Helicobacter pylori Eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; ATP Binding Cassette Transport | 2017 |
[Eosinophilic gastritis after helicobacter pylori eradication].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biop | 2008 |
[Acute psychosis induced by a Helicobacter pylori (H. pylori)-eradication treatment with amoxicillin, clarithromycin and pantoprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2010 |
Opportunistic streptococcal gastritis in a patient with ulcerative colitis mimicking gastric involvement by inflammatory bowel disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Azathioprine; Breath Tests; Colitis, Ulcerative; Dru | 2010 |
[Primary antibiotic resistance of Helicobacter pylori strains and eradication rate according to gastroduodenal disease in Korea].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Chronic Di | 2011 |
[Clinical signs of Cushing's syndrome after long-term local application of steroid in the oral cavity].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Topical; Adult; Anti-Inflammatory Agents; A | 2012 |
Pantoprazole in severe acid-peptic disease: the effectiveness and safety of 5 years' continuous treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Cell Count; | 2005 |
Thyroxine in goiter, H. pylori infection, and gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adsorption; Anti-Ulcer Agents; Benzimidazoles; Biological A | 2006 |
Cure of autoimmune gastritis by Helicobacter pylori eradication in a 21-year-old male.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Autoimmune Diseases; | 1998 |